| Literature DB >> 35843047 |
Emma Prower1, Sophie Hadfield1, Rohit Saha1, Timothy Woo1, Kar Mun Ang2, Victoria Metaxa3.
Abstract
PURPOSE: Critical Care Outreach Teams (CCOTs) have been associated with improved outcomes in patients with haematological malignancy (HM). This study aims to describe CCOT activation by patients with HM before and during the Covid-19 pandemic, assess amny association with worse outcomes, and examine the psychological impact on the CCOT.Entities:
Keywords: Critical care outreach team; Haematological malignancy; Pandemic; Psychological distress
Mesh:
Year: 2022 PMID: 35843047 PMCID: PMC9282870 DOI: 10.1016/j.jcrc.2022.154109
Source DB: PubMed Journal: J Crit Care ISSN: 0883-9441 Impact factor: 4.298
Baseline characteristics of patients with HM reviewed by the CCOT.
| Baseline | Surge | Non-surge | p-value | ||
|---|---|---|---|---|---|
| Female | 39 (37.5%) | 20 (50.0%) | 0.19 | 43 (45.7%) | 0.25 |
| Mean (SD) | 55.4 (14.1) | 51.3 (13.8) | 0.11 | 56.5 (13.4) | 0.57 |
| Acute lymphoblastic leukaemia | 6 (5.8%) | 4 (10.0%) | 0.46 | 2 (2.1%) | 0.29 |
| Acute myeloid leukaemia | 27 (26.0%) | 4 (10.0%) | 0.04 | 17 (18.1%) | 0.23 |
| Aplastic anaemia | 5 (4.8%) | 2 (5.0%) | 1 | 1 (1.1%) | 0.22 |
| Chronic lymphocytic leukaemia | 1 (1.0%) | 2 (5.0%) | 0.19 | 3 (3.2%) | 0.35 |
| Chronic myeloid leukaemia | 2 (1.9%) | 1 (2.5%) | 1 | 3 (3.2%) | 0.67 |
| Multiple myeloma | 11 (10.6%) | 5 (12.5%) | 0.77 | 19 (20.2%) | 0.07 |
| Myelodysplastic syndrome | 13 (12.5%) | 6 (15.0%) | 0.78 | 7 (7.4%) | 0.35 |
| Non-Hodgkin's lymphoma | 39 (37.5%) | 16 (40.0%) | 0.85 | 40 (42.6%) | 0.56 |
| Hodgkin's lymphoma | 0 (0%) | 0 (0%) | – | 2 (2.1%) | – |
| Mean (SD) | 3.64 (1.48) | 3.43 (1.60) | 0.45 | 3.76 (1.40) | 0.59 |
| For cardiopulmonary resuscitation | 99 (95.2%) | 38 (95.0%) | 1 | 89 (94.7%) | 1 |
| Mean (SD) | 1.82 (1.60) | 2.03 (2.11) | 0.57 | 1.96 (2.19) | 0.61 |
| Mean (SD) | 98.2 (20.9) | 93.2 (22.0) | 0.22 | 93.9 (18.9) | 0.13 |
| Mean (SD) | 92.6 (46.7) | 94.6 (51.3) | 0.83 | 104 (108) | 0.33 |
| Mean (SD) | 129 (119) | 120 (93.9) | 0.64 | 131 (121) | 0.92 |
| Mean (SD) | 4.99 (11.8) | 6.14 (11.6) | 0.6 | 5.55 (16.6) | 0.78 |
CCOT: Critical Care Outreach Team; HM: haematological malignancy; NEWS: National Early Warning Score.
CCOT review profile and outcomes of HM patients.
| Pre-pandemic | Surge | p-value | Non-surge | p-value | |
|---|---|---|---|---|---|
| Bedside | 63 (60.6%) | 24 (60.0%) | 1 | 58 (61.7%) | 0.54 |
| Remote | 37 (35.6%) | 13 (32.5%) | 28 (29.8%) | ||
| Missing | 4 (3.8%) | 3 (7.5%) | 8 (8.5%) | ||
| Mean (SD) | 22.0 (25.3) | 14.5 (17.2) | 13.8 (14.9) | ||
| Missing | 41 (39.4%) | 16 (40.0%) | 36 (38.3%) | ||
| Y | 44 (42.3%) | 19 (47.5%) | 0.57 | 33 (35.1%) | 0.38 |
| N | 60 (57.7%) | 21 (52.5%) | 61 (64.9%) | ||
| Alive | 31 (77.5%) | 10 (100%) | 0.17 | 36 (78.3%) | 1 |
| Dead | 9 (22.5%) | 0 (0.0%) | 10 (21.7%) | ||
| Mean (SD) | 29.0 (23.1) | 41.5 (55.8) | 39.3 (32.1) | ||
| Alive | 71 (68.3%) | 29 (72.5%) | 0.69 | 67 (71.3%) | 0.76 |
| Dead | 33 (31.7%) | 11 (27.5%) | 27 (28.7%) | ||
| 40 | 10 | 46 |
CCOT: Critical Care Outreach Team; HM: haematological malignancy.
Fig. 1Type of CCOT review pre- and during the pandemic.
CCOT: Critical Care Outreach Team.
Fig. 2Time to CCOT pre- and during the pandemic.